Key Sessions
Niklas Engler
Next Generation Process Development and Manufacturing for Cell and Gene Therapies - Improving Efficiencies and Reducing Cost of Goods
F. Hoffmann-La Roche
Thomas Kelly
When will we have a clone? An industry perspective on the typical CLD timeline
Johnson & Johnson Innovative Medicine
Xiuju (Sue) Lu
Remaining GMP Compliant – Changing Processes
FDA
Marinna Madrid
An autonomous Biomanufacturing platform to scale production of autologous iPSC-derived cell therapies
Cellino